May 22, 2024 10:41 AM EDT
News Briefing

Dyne's $305M of­fer­ing; Nanobi­otix de­lays Ph2 read­out

ENDPOINTS

Dyne Ther­a­peu­tics ex­pects to net $305M in stock sale: The com­pa­ny on Mon­day dropped up­dat­ed stock-mov­ing re­sults for its my­oton­ic dy­s­tro­phy type …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times